The GAL9-TIM3 signaling pathway is known to suppress anti-tumor immunity and contribute to T cell exhaustion [31], with GAL9 treatment of NK cells in vitro suppressing effector function [38, 39]. Here, LGALS9 is linked to neoplasm.